Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 4:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 1,512 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Saline 0.9% Clear all
Completed Phase 4 Interventional Results available

Bacteriostatic Normal Saline Versus Lidocaine for Intradermal Anesthesia

NCT04495868
View directory record Official record
Conditions
Chronic Pain
Interventions
Bacteriostatic Normal Saline, 1% Lidocaine
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 21, 2026, 4:01 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Belcesiran in Patients With AATLD

NCT04764448
View directory record Official record
Conditions
Alpha 1-Antitrypsin Deficiency
Interventions
Belcesiran, Placebo
Drug · Other
Lead sponsor
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
La Jolla, California • Gainesville, Florida • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 21, 2026, 4:01 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Phase 2 Trial of the Immunogenicity and Safety of CVXGA Intranasal COVID Vaccine in Healthy Adults

NCT05736835
View directory record Official record
Conditions
COVID-19
Interventions
CVXGA
Biological
Lead sponsor
CyanVac LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
227 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
10
States / cities
San Diego, California • Boise, Idaho • Sioux City, Iowa + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 21, 2026, 4:01 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease

NCT02760433
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Olokizumab, Placebo
Drug
Lead sponsor
R-Pharm International, LLC
Industry
Eligibility
18 Years and older
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
50
States / cities
Phoenix, Arizona • Hot Springs, Arkansas • Covina, California + 44 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 21, 2026, 4:01 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Comparison of Chloroprocaine vs Lidocaine for Epidural Anesthesia in Cesarean Delivery

NCT03414359
View directory record Official record
Conditions
Surgical Anesthesia, Cesarean Section
Interventions
2% Lidocaine, 3% Chloroprocaine
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Apr 13, 2020 · Synced Oct 21, 2026, 4:01 PM EDT
Completed Phase 2 Interventional Results available

Targeted Dose Finding of Canakinumab (ACZ885) for Management of Acute Flare in Refractory or Contraindicated Gout Patients

NCT00798369
View directory record Official record
Conditions
Acute Gout
Interventions
Canakinumab, Triamcinolone acetonide
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
27
States / cities
Anniston, Alabama • Birmingham, Alabama • Buena Park, California + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2012 · Synced Oct 21, 2026, 4:01 PM EDT
Completed No phase listed Observational

Cystic Breast Masses by Contrast Enhanced Ultrasound (CEUS)

NCT02887937
View directory record Official record
Conditions
Breast Cancer
Interventions
Definity
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 15, 2018 · Synced Oct 21, 2026, 4:01 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older

NCT04537208
View directory record Official record
Conditions
COVID-19 (Healthy Volunteers)
Interventions
CoV2 preS dTM-AF03 (low-dose), CoV2 preS dTM-AF03 (high-dose), CoV2 preS dTM-AS03 (low-dose), CoV2 preS dTM-AS03 (high-dose), CoV2 preS dTM (high-dose) without adjuvant, Placebo (0.9% normal saline)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
441 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
11
States / cities
Birmingham, Alabama • Rolling Hills Estates, California • Hollywood, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 21, 2026, 4:01 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Study of Glucagon, Ghrelin and Growth Hormone as Counterregulatory Hormones

NCT01795235
View directory record Official record
Conditions
Healthy
Interventions
Saline, Glucagon, Placebo, Atenolol
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 30 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 20, 2013 · Synced Oct 21, 2026, 4:01 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Treatment Effects of Subcutaneous Injections of Pentosan Polysulfate Sodium vs Placebo in Participants With Knee OA Pain

NCT04809376
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Pentosan Polysulfate Sodium twice weekly, Placebo (Sodium Chloride Injection, 0.9%), Pentosan Polysulfate Sodium Fixed Dose, Pentosan Polysulfate Sodium once weekly
Drug
Lead sponsor
Paradigm Biopharmaceuticals USA (INC)
Industry
Eligibility
18 Years and older
Enrollment
602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
29
States / cities
Tempe, Arizona • Tucson, Arizona • Cerritos, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Oct 21, 2026, 4:01 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis

NCT02473952
View directory record Official record
Conditions
Myasthenia Gravis, Generalized
Interventions
IGIV-C, Placebo
Drug
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years to 85 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
15
States / cities
Phoenix, Arizona • Orange, California • New Haven, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 21, 2026, 4:01 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Irritation and Sensitization of Chlorhexidine Gluconate (CHG) Cloth

NCT02224625
View directory record Official record
Conditions
Surgery
Interventions
2% CHG Cloth solution, Vehicle Cloth, Active Comparator, Saline, SLS
Drug · Device · Other
Lead sponsor
Medline Industries
Industry
Eligibility
16 Years and older
Enrollment
249 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Butte, Montana
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Oct 21, 2026, 4:01 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Study of OsrhAAT or Placebo in Healthy Volunteers

NCT05315921
View directory record Official record
Conditions
Emphysema Secondary to Congenital AATD
Interventions
OsrhAAT 1 mg/kg IV, OsrhAAT 3 mg/kg IV, OsrhAAT 10 mg/kg IV, OsrhAAT 20 mg/kg IV, OsrhAAT 40 mg/kg IV, OsrhAAT 60 mg/kg IV
Drug
Lead sponsor
Healthgen Biotechnology Corp.
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2022 · Synced Oct 21, 2026, 4:01 PM EDT
Terminated Phase 2 Interventional Results available

High Dose Intravenous Ascorbic Acid in Severe Sepsis

NCT02734147
View directory record Official record
Conditions
Sepsis
Interventions
Ascorbic Acid, Normal Saline
Drug · Other
Lead sponsor
Christiana Care Health Services
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Feb 16, 2021 · Synced Oct 21, 2026, 4:01 PM EDT
Recruiting Phase 2 Interventional

IVIG for Infection Prevention After CAR-T-Cell Therapy

NCT05952804
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
Immune Globulin Infusion (Human), 10% Solution, Anti-CD19 CAR T Cells Preparation, Saline, Biospecimen Collection, Survey Administration, Electronic Health Record Review
Biological · Other · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
7
States / cities
Duarte, California • Miami, Florida • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 21, 2026, 4:01 PM EDT
Completed Phase 1 Interventional

A Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Modified Vaccinia Ankara (MVA)-Mosaic OR Ad26.Mos4.HIV Plus a Combination of Mosaic and Clade C gp140 Protein in Human Immunodeficiency Virus (HIV) Type 1 Infected Adults on Suppressive Antiretroviral Treatment

NCT03307915
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
Ad26.Mos4.HIV, MVA-Mosaic, Clade C gp140 + Mosaic gp140, Placebo
Biological · Drug
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 21, 2026, 4:01 PM EDT
Active, not recruiting Phase 3 Interventional

The HeLiX (Hemorrhage During Liver Resection: traneXamic Acid) Trial

NCT02261415
View directory record Official record
Conditions
Cancer, Tumour, Surgery
Interventions
Tranexamic acid (TXA), Normal saline
Drug
Lead sponsor
Sunnybrook Health Sciences Centre
Other
Eligibility
18 Years and older
Enrollment
1,386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 26, 2022 · Synced Oct 21, 2026, 4:01 PM EDT
Completed Phase 3 Interventional Results available

CEUS Evaluation of Hypoxic Ischemic Injury

NCT03549520
View directory record Official record
Conditions
Hypoxic-Ischemic Encephalopathy, Brain Ischemia Hypoxia
Interventions
Sulfur hexafluoride lipid-type A microspheres
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
1 Minute to 18 Months
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Oct 21, 2026, 4:01 PM EDT
Terminated Phase 4 Interventional Results available

Flumazenil for Hypoactive Delirium Secondary to Benzodiazepine Exposure

NCT02899156
View directory record Official record
Conditions
Hypoactive Delirium
Interventions
Flumazenil, Placebo
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 23, 2020 · Synced Oct 21, 2026, 4:01 PM EDT
Completed Phase 4 Interventional Results available

Low Dose Ketamine for Blunt Thoracic Trauma

NCT06236113
View directory record Official record
Conditions
Blunt Injury of Thorax, Multiple Rib Fractures, Involving Three Ribs
Interventions
Ketamine 1 Mg/mL-NaCl 0.9% Intravenous Solution
Drug
Lead sponsor
North Memorial Health Care
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Robbinsdale, Minnesota
Source: ClinicalTrials.gov public record
Updated May 21, 2024 · Synced Oct 21, 2026, 4:01 PM EDT
Completed Phase 2 Interventional Results available

Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer

NCT00787761
View directory record Official record
Conditions
Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
anti-thymocyte globulin, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, tacrolimus, nonmyeloablative allogeneic HSCT
Biological · Drug · Procedure
Lead sponsor
Northside Hospital, Inc.
Other
Eligibility
Up to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 1, 2012 · Synced Oct 21, 2026, 4:01 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Prophylactic Racemic Epinephrine in Anterior Cervical Discectomy and Fusion

NCT02724761
View directory record Official record
Conditions
Dysphagia, Dysphonia, Postoperative Pain
Interventions
Racemic Epinephrine, Placebo (for racemic epinephrine)
Drug
Lead sponsor
Andrew Chung
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 31, 2016 · Synced Oct 21, 2026, 4:01 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of the Effectiveness of ST266 Ophthalmic Drops Compared to Placebo to Treat Allergic Conjunctivitis

NCT02978183
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
ST266, Saline (0.9% NaCl)
Biological · Drug
Lead sponsor
Noveome Biotherapeutics, formerly Stemnion
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Andover, Massachusetts • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Oct 21, 2026, 4:01 PM EDT
Completed Phase 2 Interventional

A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia

NCT02326454
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
talaporfin sodium, Saline, Drug Activator 100 J/cm, Drug Activator 200 J/cm
Drug · Device
Lead sponsor
Light Sciences Oncology
Industry
Eligibility
40 Years and older · Male only
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
41
States / cities
Anniston, Alabama • Huntsville, Alabama • Anchorage, Alaska + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2018 · Synced Oct 21, 2026, 4:01 PM EDT